Yip Lian Yee, Chan Eric Chun Yong
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore (L.Y.Y., E.C.Y.C.); and Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR), Singapore (L.Y.Y.).
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore (L.Y.Y., E.C.Y.C.); and Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR), Singapore (L.Y.Y.)
Drug Metab Dispos. 2015 Oct;43(10):1619-31. doi: 10.1124/dmd.115.063750. Epub 2015 May 15.
A broader understanding of factors underlying interindividual variation in pharmacotherapy is important for our pursuit of "personalized medicine." Based on knowledge gleaned from the investigation of human genetics, drug-metabolizing enzymes, and transporters, clinicians and pharmacists are able to tailor pharmacotherapies according to the genotype of patients. However, human host factors only form part of the equation that accounts for heterogeneity in therapeutic outcome. Notably, the gut microbiota possesses wide-ranging metabolic activities that expand the metabolic functions of the human host beyond that encoded by the human genome. In this review, we first illustrate the mechanisms in which gut microbes modulate pharmacokinetics and therapeutic outcome. Second, we discuss the application of metabonomics in deciphering the complex host-gut microbiota interaction in pharmacotherapy. Third, we highlight an integrative approach with particular mention of the investigation of gut microbiota using culture-based and culture-independent techniques to complement the investigation of the host-gut microbiota axes in pharmaceutical research.
深入理解药物治疗中个体间差异的潜在因素对于我们追求“个性化医疗”至关重要。基于从人类遗传学、药物代谢酶和转运体研究中获得的知识,临床医生和药剂师能够根据患者的基因型调整药物治疗方案。然而,人类宿主因素只是导致治疗结果异质性的部分原因。值得注意的是,肠道微生物群具有广泛的代谢活性,其扩展了人类宿主的代谢功能,超出了人类基因组所编码的范围。在这篇综述中,我们首先阐述肠道微生物调节药代动力学和治疗结果的机制。其次,我们讨论代谢组学在解读药物治疗中复杂的宿主-肠道微生物群相互作用方面的应用。第三,我们强调一种综合方法,特别提及使用基于培养和不依赖培养的技术研究肠道微生物群,以补充药物研究中宿主-肠道微生物群轴的研究。